Crispr Therapeutics AG (NASDAQ:CRSP) was the target of a significant decrease in short interest in the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decrease of 6.1% from the November 28th total of 3,620,000 shares. Currently, 9.9% of the shares of the company are sold short. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio is presently 3.4 days.
Several research analysts recently issued reports on the stock. BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 1st. Chardan Capital reissued a “buy” rating and set a $72.50 price target on shares of Crispr Therapeutics in a report on Monday, November 18th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Roth Capital increased their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $71.38.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock valued at $3,620,760 in the last quarter. Insiders own 21.40% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after acquiring an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its position in Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after acquiring an additional 375 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Crispr Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after acquiring an additional 386 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in Crispr Therapeutics during the fourth quarter worth approximately $26,000. Finally, Webster Bank N. A. acquired a new stake in Crispr Therapeutics during the fourth quarter worth approximately $26,000. Institutional investors and hedge funds own 49.83% of the company’s stock.
Shares of CRSP stock traded down $1.30 during trading hours on Monday, hitting $58.33. The company’s stock had a trading volume of 1,116,434 shares, compared to its average volume of 1,005,297. The business has a fifty day moving average of $65.14 and a 200-day moving average of $52.14. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -126.80 and a beta of 3.20. Crispr Therapeutics has a twelve month low of $29.34 and a twelve month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. On average, equities analysts expect that Crispr Therapeutics will post 0.65 EPS for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Equal Weight Rating
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.